Nexavar

(Sorafenib)

ApprovedSmall molecule

Sorafenib is used to treat certain types of cancer, including liver cancer, kidney cancer, and thyroid cancer. It works by slowing or stopping the growth of cancer cells in the body.[2] Nexavar is currently approved and in use across 96 indications[4].[1]

Nexavar is one of 1591 small molecule programs targeting Glioma. It is currently in Approved.

Indications

620

Total Trials

Active Trials

1,590

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Pancreatic CarcinomaActive, not recruiting

Collecting Duct CarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

AstrocytomaActive, not recruiting

MetastasisActive, not recruiting

Prostate AdenocarcinomaApproved

Gallbladder CarcinomaActive, not recruiting

Clear Cell Renal CarcinomaActive, not recruiting

Nasopharyngeal CarcinomaActive, not recruiting

GliomaPhase 2

Active, not recruiting

Pancreatic CarcinomaPhase 1

Active, not recruiting

Collecting Duct CarcinomaPhase 2

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

AstrocytomaPhase 2

Active, not recruiting

MetastasisPhase 1/Phase 2

Active, not recruiting

Prostate AdenocarcinomaApproved

Approved

Gallbladder CarcinomaPhase 2

Active, not recruiting

Clear Cell Renal CarcinomaPhase 1

Active, not recruiting

Nasopharyngeal CarcinomaPhase 2

Active, not recruiting

Showing 10 of 96 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Nexavar

Bayer

Approved

20 2

Tykerb

GSK

Preclinical

80 3

Prolia

Amgen

Preclinical

14 4

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Vfend

PPrism Pharmaceuticals

Paracetamol

1 9

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 10

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Hepatocellular Carcinoma

NCT05822752

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT04039607

Phase 2Recruiting

Breast Cancer

NCT05594095

Phase 3Active, not recruiting

Liver Cancer

NCT03533582

Q4 2027

Phase 2Recruiting

Patients With Advanced Solid Tumors

NCT02029001

Phase 1Active, not recruiting

Leukemia

NCT03132454

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma52 trials

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

Unknown status·SSouthwest Hospital, China·N/A·NCT03097848·450 enrolled

Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT00752063·52 enrolled

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Terminated·NNew Mexico Cancer Research Alliance·Phase 2·NCT01032850·15 enrolled

Show 49 more trials

Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)

Terminated·NNational Health Research Institutes, Taiwan·Phase 1/2·NCT00971126·3 enrolled

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Completed· Eisai logo

Eisai·Phase 1/2·NCT01271504·102 enrolled

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04039607·732 enrolled

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Completed·SSumitomo Pharma Co., Ltd.·Phase 1·NCT02354898·60 enrolled

Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)

Unknown status·UUniversity of Turin, Italy··NCT01230697·60 enrolled

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Terminated·AAbbott·Phase 3·NCT01009593·1,035 enrolled

Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01004003·125 enrolled

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Terminated·TTaiRx, Inc.·Phase 2·NCT03582618·12 enrolled

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Terminated·KKathy Miller·Phase 1/2·NCT02575339·11 enrolled

A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Completed· Roche logo

Roche·Phase 3·NCT03434379·558 enrolled

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Withdrawn· Amgen logo

Amgen·Phase 1/2·NCT02227914

4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma

Completed·44SC AG·Phase 2·NCT00943449·57 enrolled

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Unknown status·VVicus Therapeutics·Phase 2·NCT01265576·20 enrolled

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Unknown status· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2/3·NCT03794440·595 enrolled

Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed·TThe University of Hong Kong·Phase 2·NCT02716766·46 enrolled

Influence of Sarcopenia in Hepatocellular Carcinoma Patients

Unknown status·SSohag University··NCT06177496·600 enrolled

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Completed· GSK logo

GSK·Phase 1/2·NCT01258608·101 enrolled

Sorafenib With TACE to Treat Hepatocellular Carcinoma

Completed·UUniversity of Bern·Phase 1·NCT00478374·21 enrolled

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Completed· BeiGene logo

BeiGene·Phase 3·NCT03412773·684 enrolled

Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

Unknown status·—·Phase 2·NCT00844688·30 enrolled

Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

Terminated·—·Phase 3·NCT04709380·36 enrolled

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04770896·557 enrolled

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Completed· Eisai logo

Eisai·Phase 3·NCT01761266·954 enrolled

Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)

Unknown status·—·Phase 2·NCT01170104·63 enrolled

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma

Terminated·BBoston Scientific Corporation·Phase 3·NCT02460991·2 enrolled

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

Active, not recruiting· AbbVie logo

AbbVie·Phase 2·NCT05822752·130 enrolled

Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma

Completed·MMedical University of Vienna·Phase 1/2·NCT00768937·22 enrolled

A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

Completed· Roche logo

Roche·Phase 1·NCT01308723·6 enrolled

Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma

Completed·SSohag University··NCT04553458·407 enrolled

Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

Unknown status·SSun Yat-sen University··NCT05889949·200 enrolled

Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)

Completed·NNational Taiwan University Hospital·Phase 2·NCT00464919·50 enrolled

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed·AAegera Therapeutics·Phase 1/2·NCT00882869·75 enrolled

Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial

Unknown status·PPD Dr. med. Matthias Dollinger·Phase 2·NCT01272557·170 enrolled

Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC)

Completed·SSingapore Clinical Research Institute·Phase 1/2·NCT00712790·35 enrolled

A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Completed· GSK logo

GSK·Phase 1·NCT00712855·23 enrolled

Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan

Completed· Bayer logo

Bayer··NCT01411436·1,637 enrolled

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT00105443·602 enrolled

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety

Completed· Bayer logo

Bayer··NCT01908322·19 enrolled

Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib

Completed· Bayer logo

Bayer··NCT00812175·3,371 enrolled

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

Completed· Bayer logo

Bayer··NCT01933945·1,676 enrolled

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Completed· Bayer logo

Bayer·Phase 3·NCT00494299·458 enrolled

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT00492752·226 enrolled

Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China

Completed· Bayer logo

Bayer··NCT01839630·302 enrolled

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

Unknown status·SSinocelltech Ltd.·Phase 2/3·NCT04560894·405 enrolled

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment

Terminated· Bayer logo

Bayer··NCT03644511·3 enrolled

Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed·IIstituto Clinico Humanitas·Phase 2·NCT00490685·142 enrolled

Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy

Completed· Bayer logo

Bayer··NCT01539681·234 enrolled

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Completed· Bayer logo

Bayer·Phase 2·NCT00044512·137 enrolled

Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC)

Completed·IItalian Trial in Medical Oncology·Phase 2·NCT00619541·46 enrolled

Renal Cell Carcinoma11 trials

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

Completed·UUniversity of Chicago·Phase 3·NCT00606866·57 enrolled

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Completed· Bayer logo

Bayer·Phase 3·NCT00111020·2,567 enrolled

Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00480389·19 enrolled

Show 8 more trials

Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma

Terminated·CCentro di Riferimento Oncologico - Aviano·Phase 2·NCT01342627·4 enrolled

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

Completed·AAVEO Pharmaceuticals, Inc.·Phase 3·NCT02627963·350 enrolled

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Completed·—·Phase 1·NCT02406521·30 enrolled

A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®

Completed· Bayer logo

Bayer··NCT00771147·71 enrolled

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Completed· Bayer logo

Bayer·Phase 2·NCT00117637·189 enrolled

Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Completed· Bayer logo

Bayer··NCT01508364·20 enrolled

Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

Completed· Bayer logo

Bayer··NCT01411423·3,305 enrolled

Sequential Study to Treat Renal Cell Carcinoma

Completed·SSponsor GmbH·Phase 3·NCT00732914·272 enrolled

Sorafenib9 trials

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT07463651·594 enrolled

Bioequivalence Study of Sorafenib Tablet and Nexavar

Completed·YYabao Pharmaceutical Group·Phase 1·NCT02599337·36 enrolled

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Completed·MMina Alpha Limited·Phase 2·NCT04710641·8 enrolled

Show 6 more trials

Sorafenib for Imatinib/Sunitinib-failed GIST

Completed·SSamsung Medical Center·Phase 2·NCT01091207·39 enrolled

Trial of TRC105 and Sorafenib in Patients With HCC

Completed·TTracon Pharmaceuticals Inc.·Phase 1/2·NCT02560779·27 enrolled

Second Line Sorafenib After Pazopanib in Patients With RCC

Terminated·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02122003·16 enrolled

HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC

Completed·SSun Yat-sen University·Phase 3·NCT02856126·214 enrolled

Sorafenib/Docetaxel Dose Escalation Trial

Completed· Bayer logo

Bayer·Phase 1·NCT00562523·17 enrolled

Sorafenib Long Term Extension Program

Completed· Bayer logo

Bayer·Phase 3·NCT00625378·206 enrolled

Melanoma7 trials

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Completed· Bayer logo

Bayer·Phase 3·NCT00111007·270 enrolled

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00349206·69 enrolled

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

Completed·—·Phase 1·NCT00565968·20 enrolled

Show 4 more trials

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Unknown status·SSan Diego Pacific Oncology & Hematology Associates·Phase 1/2·NCT00538005·54 enrolled

Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine

Completed·UUniversity of Zurich·Phase 2·NCT00794235·12 enrolled

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Completed·CClavis Pharma·Phase 2·NCT00498836·18 enrolled

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Completed· Bayer logo

Bayer·Phase 2·NCT00110994·101 enrolled

Liver Cancer7 trials

Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer

Completed·RRobin Kate Kelley·Phase 2·NCT03439891·16 enrolled

Sorafenib Tosylate in Treating Patients With Liver Cancer That Can Be Removed by Surgery

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01182272·36 enrolled

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT01075113·16 enrolled

Show 4 more trials

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT01730937·193 enrolled

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

Immunotherapy for Advanced Liver Cancer

Suspended·MMirror Biologics, Inc.·Phase 2/3·NCT05033522·150 enrolled

Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01900002·40 enrolled

75 more indications

Non-Small Cell Lung Cancer7 trials

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00543335·10 enrolled

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00454194·110 enrolled

Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer

Completed·NNational Cancer Centre, Singapore·Phase 1·NCT00870532·52 enrolled

Show 4 more trials

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

Terminated·—·Phase 1/2·NCT00417248·8 enrolled

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00954278·24 enrolled

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

Completed· Bayer logo

Bayer·Phase 3·NCT00863746·703 enrolled

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Completed·CChinese Society of Lung Cancer·Phase 2·NCT00922584·65 enrolled

Kidney Cancer4 trials

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00126503·73 enrolled

Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00378703·361 enrolled

Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer

Completed·SStanford University·Phase 2·NCT00854620·9 enrolled

Show 1 more trial

Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer

Withdrawn· Bayer logo

Bayer··NCT01353794

Thyroid Cancer4 trials

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03630120·6 enrolled

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02143726·35 enrolled

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Completed· Bayer logo

Bayer·Phase 3·NCT00984282·417 enrolled

Show 1 more trial

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Completed· Bayer logo

Bayer··NCT02303444·667 enrolled

Pancreatic Cancer3 trials

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Completed·NNYU Langone Health·Phase 2·NCT00696696·45 enrolled

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

Active, not recruiting·HHonorHealth Research Institute·Phase 2·NCT05068752·12 enrolled

Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT02349867·23 enrolled

Leukemia3 trials

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00665990·49 enrolled

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03132454·32 enrolled

Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02474290·202 enrolled

Multiple Myeloma3 trials

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00253578·40 enrolled

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Completed·MMayo Clinic·Phase 1/2·NCT00474929·103 enrolled

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00536575·13 enrolled

Patients With Advanced Solid Tumors3 trials

Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors

Completed·VVirginia Commonwealth University·Phase 1·NCT01450384·37 enrolled

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting·CCentre Leon Berard·Phase 2·NCT02029001·900 enrolled

Myelodysplastic Syndrome3 trials

Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Completed·IIndiana University School of Medicine·Phase 1·NCT00875745·15 enrolled

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02196857·16 enrolled

Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01254890·60 enrolled

Metastatic Melanoma3 trials

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

Completed· Bayer logo

Bayer·Phase 2·NCT00492297·83 enrolled

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

Completed·UUniversity Hospital Schleswig-Holstein·Phase 2·NCT00623402·55 enrolled

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Completed·MMt. Sinai Medical Center, Miami·Phase 2·NCT00483301·34 enrolled

Ovarian Cancer3 trials

Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer

Completed·JJSehouli·Phase 2·NCT01047891·174 enrolled

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00390611·85 enrolled

Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer

Terminated·—·Phase 1/2·NCT00526799·30 enrolled

Soft Tissue Sarcoma3 trials

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT00880542·7 enrolled

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00217620·51 enrolled

BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas

Completed·IIstituto Clinico Humanitas·Phase 2·NCT00406601·69 enrolled

Breast Cancer3 trials

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

BAY43-9006 - Phase II in Advanced Breast Cancer

Completed· Bayer logo

Bayer·Phase 2·NCT00101400·54 enrolled

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Completed· Bayer logo

Bayer·Phase 3·NCT01234337·537 enrolled

Patients With Solid Tumors2 trials

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

Completed·SSafi Shahda·Phase 1·NCT00572078·27 enrolled

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Completed·HHMeany·Phase 1·NCT01518413·17 enrolled

Prospective2 trials

HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial

Unknown status·SSun Yat-sen University·Phase 2·NCT04135690·60 enrolled

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT07264010·87 enrolled

Small Cell Lung Cancer2 trials

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Terminated·—·Phase 2·NCT00726986·18 enrolled

Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer

Completed·HHealthPartners Institute·Phase 1·NCT00466232·16 enrolled

Randomized2 trials

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00939627·55 enrolled

Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail

Completed·SSun Yat-sen University·Phase 4·NCT02961998·116 enrolled

Hepatocellular Cancer2 trials

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer

Terminated·EEmory University·Phase 2·NCT01334710·3 enrolled

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Unknown status·—·Phase 2·NCT03971201·200 enrolled

Neuroendocrine Tumors2 trials

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00605566·22 enrolled

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Completed·—·Phase 1·NCT00942682·21 enrolled

Thrombosis2 trials

A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis

Unknown status·HHuazhong University of Science and Technology·Phase 4·NCT03178656·54 enrolled

Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis

Completed·PPeking University·Phase 2·NCT03009461·64 enrolled

Thyroid Carcinoma2 trials

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Completed· Bayer logo

Bayer·Phase 2·NCT02114658·18 enrolled

Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma

Completed·LLeiden University Medical Center·Phase 2·NCT00887107·32 enrolled

Maintenance Therapy1 trial

Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allo-HSCT for Patients With FLT3-ITD AML

Completed·NNanfang Hospital, Southern Medical University··NCT04788420·456 enrolled

Induction Chemotherapy1 trial

Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy

Terminated·NNational Cancer Center, Korea·Phase 2·NCT01159327·13 enrolled

Prophylaxis1 trial

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

Recruiting·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT06532084·88 enrolled

Salivary Gland Cancer1 trial

Activity of Sorafenib in Salivary Gland Cancer

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01703455·37 enrolled

Acute Lymphoblastic Leukemia1 trial

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02779283·7 enrolled

Chemotherapy1 trial

Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy

Completed·KKindai University·Phase 1/2·NCT00933816·37 enrolled

Acute Monocytic Leukemia1 trial

Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2/3·NCT05313958·43 enrolled

Fallopian Tube Cancer1 trial

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096200·44 enrolled

Metastatic Cancer1 trial

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00112905·27 enrolled

Carboplatin1 trial

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Completed·—·Phase 2·NCT00647426·7 enrolled

Unresectable1 trial

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01498952·6 enrolled

Adjuvant Therapy1 trial

A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01041482·140 enrolled

Bevacizumab1 trial

Bevacizumab in Multiple Phase I Combinations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00543504·343 enrolled

Barrett's esophagus1 trial

The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

Terminated·UUniversity of Chicago·N/A·NCT00619242·3 enrolled

Squamous Cell Carcinoma1 trial

Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)

Withdrawn·BBritish Columbia Cancer Agency·Phase 1·NCT00627835

Metastasis1 trial

Sorafenib-RT Treatment for Liver Metastasis (SLIM)

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT00892424·54 enrolled

Pulmonary Arterial Hypertension1 trial

Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)

Completed·UUniversity of Chicago·Phase 1·NCT00452218·12 enrolled

Postoperative Adjuvant Treatment1 trial

Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC

Unknown status·SSun Yat-sen University·Phase 3·NCT04143191·158 enrolled

Advanced1 trial

HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC

Unknown status·SSun Yat-sen University·Phase 3·NCT03468231·300 enrolled

Glioblastoma1 trial

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00734526·18 enrolled

Colorectal Cancer1 trial

Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer

Terminated·AAIO-Studien-gGmbH·Phase 2·NCT00889343·101 enrolled

Locally-advanced Rectal Cancer1 trial

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT01376453·18 enrolled

Head and Neck Cancer1 trial

Study of Sorafenib/Cetuximab in Head and Neck Cancer

Completed·—·Phase 1/2·NCT00815295·31 enrolled

Glioblastoma Multiforme1 trial

Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00544817·47 enrolled

Cervical Cancer1 trial

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT00510250·13 enrolled

Treatment1 trial

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT04992143·20 enrolled

Gallbladder Carcinoma1 trial

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02836847·152 enrolled

Pancreatic Carcinoma1 trial

Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 1·NCT00789763·12 enrolled

Capecitabine1 trial

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma

Completed·UUniversity of Wisconsin, Madison·Phase 1/2·NCT00634751·48 enrolled

Relapsed or Refractory1 trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Chronic Lymphocytic Leukemia1 trial

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Terminated·TThomas Kipps·Phase 2·NCT01510756·4 enrolled

Advanced Malignant Solid Tumors1 trial

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

Completed·UUniversity of California, Davis·Phase 2·NCT00810394·50 enrolled

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

Type 1 Diabetes Mellitus1 trial

Efficacy and Safety of Sorafenib in New-Onset Type 1 Diabetes Mellitus

Not yet recruiting·SSecond Xiangya Hospital of Central South University·Phase 2·NCT06227221·10 enrolled

Acute Myeloid Leukemia1 trial

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Relapsed/Refractory AML1 trial

Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD

Completed·TThe University of Hong Kong·Phase 2·NCT03170895·5 enrolled

Pediatric Solid Tumors1 trial

Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02747537

Gastric Cancer1 trial

Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT01262482·41 enrolled

Prostate Cancer1 trial

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Terminated·AAccelerated Community Oncology Research Network·Phase 2·NCT00452387·22 enrolled

Liver Carcinoma1 trial

Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT00791544·13 enrolled

Neoadjuvant Therapy1 trial

SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC

Completed·TThe University of Hong Kong·Phase 2·NCT03578874·15 enrolled

Neuroblastoma1 trial

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting·GGiselle Sholler·Phase 2·NCT02559778·500 enrolled

Refractory Solid Tumors1 trial

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02143401·29 enrolled

Metastatic Renal Cell Cancer1 trial

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Completed· Bayer logo

Bayer·Phase 3·NCT00073307·903 enrolled

ESS1 trial

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Completed· Bayer logo

Bayer··NCT01412671·117 enrolled

Interaction1 trial

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

Completed· Bayer logo

Bayer·Phase 1·NCT02332031·25 enrolled

Function1 trial

Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

Completed· Bayer logo

Bayer·Phase 1·NCT00119639·32 enrolled

Renal Cancer1 trial

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

Completed· Bayer logo

Bayer··NCT01557127·205 enrolled

Hypophosphatemia1 trial

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

Terminated· Bayer logo

Bayer·Phase 1·NCT00622479·12 enrolled

Cardiovascular1 trial

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Completed· Bayer logo

Bayer·Phase 1·NCT00259129·53 enrolled

Hepatic Impairment1 trial

Hepatic Impairment Study

Completed· Bayer logo

Bayer·Phase 1·NCT00829231·45 enrolled

Non-Small Cell Lung Carcinoma1 trial

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Completed· Bayer logo

Bayer·Phase 2·NCT00101413·52 enrolled

Unspecified2 trials

Regulatory Post Marketing Surveillance Study on Nexavar®

Completed· Bayer logo

Bayer··NCT01012011·2,845 enrolled

INSIGHT - Post Marketing Surveillance

Completed· Bayer logo

Bayer··NCT00792350·791 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 20, 2005

NEXAVAR

NDA NDA021923

Sources

References

[1]
ClinicalTrials.gov — 620 trial records for Sorafenib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Nexavar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Sorafenib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Sorafenib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021923). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Nexavar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serine/threonine-Protein Kinase RAF Inhibitor; Platelet-Derived Growth Factor Receptor Beta Inhibitor; Serine/threonine-Protein Kinase B-RAF Inhibitor; Stem Cell Growth Factor Receptor Inhibitor; Tyrosine-Protein Kinase Receptor FLT3 Inhibitor; Tyrosine-Protein Kinase Receptor RET Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Bayer

Patent Landscape[6]

Patent Cliff

Dec 24, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8877933Dec 24, 2027

9737488Sep 10, 2028

Nexavar

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Trials by Indication[1]

Hepatocellular Carcinoma52 trials

Renal Cell Carcinoma11 trials

Sorafenib9 trials

Melanoma7 trials

Liver Cancer7 trials

Non-Small Cell Lung Cancer7 trials

Kidney Cancer4 trials

Thyroid Cancer4 trials

Pancreatic Cancer3 trials

Leukemia3 trials

Multiple Myeloma3 trials

Patients With Advanced Solid Tumors3 trials

Myelodysplastic Syndrome3 trials

Metastatic Melanoma3 trials

Ovarian Cancer3 trials

Soft Tissue Sarcoma3 trials

Breast Cancer3 trials

Patients With Solid Tumors2 trials

Prospective2 trials

Small Cell Lung Cancer2 trials

Randomized2 trials

Hepatocellular Cancer2 trials

Neuroendocrine Tumors2 trials

Thrombosis2 trials

Thyroid Carcinoma2 trials

Maintenance Therapy1 trial

Induction Chemotherapy1 trial

Prophylaxis1 trial

Salivary Gland Cancer1 trial

Acute Lymphoblastic Leukemia1 trial

Chemotherapy1 trial

Acute Monocytic Leukemia1 trial

Fallopian Tube Cancer1 trial

Metastatic Cancer1 trial

Carboplatin1 trial

Unresectable1 trial

Adjuvant Therapy1 trial

Bevacizumab1 trial

Barrett's esophagus1 trial

Squamous Cell Carcinoma1 trial

Metastasis1 trial

Pulmonary Arterial Hypertension1 trial

Postoperative Adjuvant Treatment1 trial

Advanced1 trial

Glioblastoma1 trial

Colorectal Cancer1 trial

Locally-advanced Rectal Cancer1 trial

Head and Neck Cancer1 trial

Glioblastoma Multiforme1 trial

Cervical Cancer1 trial

Treatment1 trial

Gallbladder Carcinoma1 trial

Pancreatic Carcinoma1 trial

Capecitabine1 trial

Relapsed or Refractory1 trial

Chronic Lymphocytic Leukemia1 trial

Advanced Malignant Solid Tumors1 trial

Gut Microbiome1 trial

Metformin1 trial

Advanced Solid Malignancies1 trial

Type 1 Diabetes Mellitus1 trial

Acute Myeloid Leukemia1 trial

Relapsed/Refractory AML1 trial

Pediatric Solid Tumors1 trial

Gastric Cancer1 trial

Prostate Cancer1 trial

Liver Carcinoma1 trial

Neoadjuvant Therapy1 trial

Neuroblastoma1 trial

Refractory Solid Tumors1 trial

Metastatic Renal Cell Cancer1 trial

ESS1 trial

Interaction1 trial